Necitumumab combined with osimertinib in the treatment of t790m negative patients

Necitumumab is a fully human IgG1 monoclonal antibody targeting EGFR. It can be used in combination with gemcitabine and cisplatin for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). Osimertinib is a first-line EGFR drug. mut is the standard treatment regimen for non-small cell lung cancer and TKI-resistant T790Mpos non-small cell lung cancer, but acquired resistance has emerged. NexituzumabTestingosimertinib in the specific setting ofEGFR TKI resistance.

The results showed that ,69% of subjects had detectable EGFR activating mutations in ctDNA, 80% of subjects had a decrease in mutation allele frequency (AF) during treatment, and 33% of subjects had ctDNA clearance, therefore nexituzumab combined with osimertinib in RP2D is feasible and tolerable. Most subjects with reduced atrial fibrillation after treatment had detectable EGFR ctDNA at baseline. Nexituzumab combined with osimertinib is active in specific cases of EGFR-TKI resistance,and in t790mneg PD (ExC A) with 1/2 generation TKI as last treatment, EGFR ex20ins post-chemotherapy PD (ExC D) and first-line osimertinibPD (ExC E) met its prespecified efficacy endpoint.

The generic drug of Nexituzumab has not yet been approved for marketing in China, and therefore it has not been included in medical insurance. The German version of the generic version of Nexituzumab available overseas800mg/50ml may cost more than RMB 10,000 per box (the price may fluctuate due to the exchange rate), which is relatively expensive. Currently, there is no generic version of Nexituzumab on the market. For more drug information and specific prices, please consult Yaode Medical Consultant.